Glenmede Trust Co. NA Increases Holdings in Boston Scientific Corporation $BSX

Glenmede Trust Co. NA boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 12.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 121,568 shares of the medical equipment provider’s stock after purchasing an additional 13,572 shares during the quarter. Glenmede Trust Co. NA’s holdings in Boston Scientific were worth $7,628,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of BSX. Renaissance Group LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth $28,064,000. Rathbones Group PLC grew its stake in Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares during the last quarter. Meiji Yasuda America Inc bought a new position in Boston Scientific in the fourth quarter worth about $4,708,000. Harvest Portfolios Group Inc. lifted its position in shares of Boston Scientific by 6.1% during the fourth quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock valued at $56,956,000 after buying an additional 34,598 shares during the last quarter. Finally, LBP AM SA grew its position in shares of Boston Scientific by 8.4% in the 4th quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock worth $41,419,000 after buying an additional 33,534 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 14,800 shares of company stock worth $781,412 in the last ninety days. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several analyst reports. Wells Fargo & Company cut their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a report on Thursday. Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday. Leerink Partners set a $60.00 price objective on Boston Scientific in a research report on Thursday. Bank of America reduced their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Royal Bank Of Canada decreased their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Performance

BSX opened at $48.45 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a fifty day moving average price of $45.95 and a 200 day moving average price of $61.70. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The stock has a market cap of $72.02 billion, a P/E ratio of 19.62, a P/E/G ratio of 1.02 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business earned $0.75 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.